期刊文献+

汉滩病毒核蛋白CTL表位肽联合不同免疫佐剂的免疫学特性研究

Immunological Characteristics of Hantaan Virus Nucleoprotein CTL Epitopes Combined with Different Immune Adjuvants
下载PDF
导出
摘要 目的:研究汉滩病毒(HTNV)核蛋白细胞毒性T淋巴细胞(CTL)表位肽联合不同免疫佐剂免疫C57BL/6小鼠后的免疫学特性,确立一种免疫效果良好的多肽免疫C57BL/6小鼠方案。方法:分别用氢氧化铝、弗氏佐剂和脂质体作为免疫佐剂与汉滩病毒核衣壳蛋白上的CTL表位肽段混合,经皮下注射免疫C57BL/6小鼠,共免疫3次,每次间隔2周;免疫结束后分离小鼠脾细胞,并分别采用ELISPOT和CTL杀伤试验进行检测。结果:HTNV核蛋白CTL表位肽联合弗氏佐剂加脂质体组小鼠脾细胞分泌IFN-γ能力和CTL杀伤能力优于其他各实验组(P<0.01)。结论:HTNVCTL表位肽联合弗氏佐剂加脂质体免疫C57BL/6小鼠效果最佳,可为HTNV多肽疫苗的免疫策略提供参考。 Objective: To establish an improved immunization protocal to immune the C57BL/6 mice with epit-ope peptides through studying immunological characteristics of Hantaan virus(HTNV) nucleoprotein CTL epitopecombined with different immune adjuvants. Methods: C57BL/6 mice were subcutaneous immunized with HTNV nu-cleoprotein CTL epitope combined with aluminum hydroxide adjuvant, Freund's adjuvant, and immunoliposome, re-spectively. Immunization was performed three times, with 2 weeks interval. After immunization, the splenocytes ofmice were isolated to detect the immunological characteristics by ELISPOT and cytotoxicity assays. Results: Com-pared with other groups, group of CTL epitope combined with Freud's adjuvant and immunoliposome showed agreater ability to secrete interferon-γ and producted stronger cytotoxicity(P0.01). Conclusion: HTNV nucleopro-tein CTL epitope combined with Freud's adjuvant and immunoliposome have an increased immune effect, provid-ing an alternative vaccination strategy.
出处 《生物技术通讯》 CAS 2016年第6期787-789,807,共4页 Letters in Biotechnology
基金 国家自然科学基金(31470890 31270978) 陕西省科技统筹创新工程计划(2013KTCL03-06) 军队重点课题(BWS13G024)
关键词 免疫佐剂 汉滩病毒 表位肽 C57BL/6小鼠 immune adjuvants Hantaan virus epitope peptides C57BL/6 mice
  • 相关文献

参考文献3

二级参考文献56

  • 1张宏梅,徐明,崔佰吉,金洪光.pH梯度法制备重酒石酸长春瑞滨脂质体[J].吉林医药学院学报,2008,29(6):320-322. 被引量:8
  • 2SISKIND GW, BENACERRAF B. Cell selection by antigen in the immune response[J]. Advlmmunol, 1969, 10:1 -50.
  • 3BURRELL LS, WHITE JL, HEM SL. Stability of aluminium- containing adjuvants during aging at room temperature [ Jl. Vac- cine, 2000, 18(21) :2188 -2192.
  • 4GUPTA RK, CHANG AC, GRIFFIN P,et al. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeles tetanus toxoid [ J]. Vaccine, 1996, 1g(15) :1412 - 1416.
  • 5HEM SL, HOGENESCH H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immu-nopotentiation [ J]. Expert Rev Vaccine, 2007, 6 (5) :685 - 698.
  • 6HUTCHISON S, BENSON RA, GIBSON VB, et al. Antigen depot is not required for alum adjuvanticity [ J]. FASEB J, 2012, 26(3) :1272 - 1279.
  • 7MUNKS MW, MCKEE AS, MACLEOD MK, et al. Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo [ J ]. Blood, 2010, 116(24) :5191 -5199.
  • 8OTT G, BARCHFELD GL, CHERNOFF D,et al. MF59 design and evaluation of a safe and potent adjuvant for human vaccines [ J]. Pharm Biotechnol, 1995, 6:277 - 296.
  • 9MOREIN B, BENGTSSON KLV. Immunomodulation by iscoms, immune stimulating complexes [ J]. Methods, 1999, 19 ( 1 ) : 94 - 102.
  • 10MOSCA F, TRITTO E, MUZZI A, et al. Molecular and celluar signatures of human vaccine adjuvants [ J ]. Proc Natl Acad Sci USA, 2008, 105(30) :10501 - 10506.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部